Evidence map›Paper›PMID 41834421›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Fluorine-18-Labeled Nucleotide Analogs Targeting Ecto-5'-Nucleotidase (CD73) for Positron Emission Tomography Imaging of Solid Tumors.

Clemens Dobelmann, Constanze C Schmies, Georg Wilhelm Rolshoven, Mirko Scortichini, Stefan Wagner, Andreas Isaak, Riham M Idris, Jennifer Dabel, Lucie Grey, Karolina Losenkova and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Clemens DobelmannEuropean Institute for Molecular Imaging (EIMI), University of Muenster, Münster, Germany.
Constanze C SchmiesPharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry University of Bonn, Bonn, Germany.
Georg Wilhelm RolshovenPharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry University of Bonn, Bonn, Germany.
Mirko ScortichiniMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Stefan WagnerDepartment of Nuclear Medicine, University Hospital Muenster, Münster, Germany.
Andreas IsaakEuropean Institute for Molecular Imaging (EIMI), University of Muenster, Münster, Germany.
Riham M IdrisPharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry University of Bonn, Bonn, Germany.
Jennifer DabelEuropean Institute for Molecular Imaging (EIMI), University of Muenster, Münster, Germany.
Lucie GreyInstitut Für Pharmazeutische und Medizinische Chemie, University of Muenster, Muenster, Germany.
Karolina LosenkovaMedicity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland.
Susanne MoschützInstitute of Bioanalytical Chemistry, Center for Biotechnology and Biomedicine, Leipzig University, Leipzig, Germany.
Haneen Al HroubPharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry University of Bonn, Bonn, Germany.
Antje KeimInstitute of Bioanalytical Chemistry, Center for Biotechnology and Biomedicine, Leipzig University, Leipzig, Germany.
Sandra HöppnerEuropean Institute for Molecular Imaging (EIMI), University of Muenster, Münster, Germany.
Jouko SandholmTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Pia BoströmDepartment of Pathology, University of Turku and Turku University Central Hospital, Turku, Finland.
Maija HollménMedicity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland.
Norbert SträterInstitute of Bioanalytical Chemistry, Center for Biotechnology and Biomedicine, Leipzig University, Leipzig, Germany.
Sven HermannEuropean Institute for Molecular Imaging (EIMI), University of Muenster, Münster, Germany.
Gennady G YegutkinMedicity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland.
Kenneth A JacobsonMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Sonja SchelhaasEuropean Institute for Molecular Imaging (EIMI), University of Muenster, Münster, Germany.
Christa E MüllerPharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry University of Bonn, Bonn, Germany.
Anna JunkerEuropean Institute for Molecular Imaging (EIMI), University of Muenster, Münster, Germany.ORCID 0000-0001-5151-0930

Funding

Development Of Drugs Acting At Adenosine ReceptorsZIADK031117 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 2009 to 2025
$10.4M
German Research Foundation EXC 2180 - 390900677 (AJ)German Research Foundation JU 2966/2-2 (AJ)Intramural NIH HHS ZIA DK031117
6 · The paper itself

Abstract

Ecto-5'-nucleotidase (CD73) is a potential new drug target for cancer immunotherapy. Its overexpression is associated with various aggressive cancers, including triple-negative breast cancer (TNBC) and pancreatic cancer, making it a promising target for diagnostic imaging. Besides antibodies, small-molecule CD73 inhibitors have been developed and are currently in clinical trials. This study aimed to develop and evaluate fluorine-18 labeled high-affinity CD73 inhibitors as tracers for the non-invasive positron emission tomography (PET) imaging of CD73 expression in cancer. Two CD73 inhibitors were selected for radiolabeling based on their high potency (K

Indexed as

5'-NucleotidaseFluorine RadioisotopesNucleotidesPositron-Emission TomographyRadiopharmaceuticalsAnimalsFemaleHumansMice5'-NucleotidaseFluorine-18Fluorine RadioisotopesNucleotidesRadiopharmaceuticals

Identifiers

PMID41834421
PMCPMC13077603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.